Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barker

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 17, 2026
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose AdalimumabAnika M Valk, Jolinde van Strien, Ninotska Derksen, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
Nature Genetics|June 27, 2015
The European Genome-phenome Archive of human data consented for biomedical researchIlkka Lappalainen, Jeff Almeida-King, Vasudev Kumanduri, et al.
JCI Insight|February 22, 2023
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding grooveTeresa Tsakok, Jake Saklatvala, Theo Rispens, et al.
The Journal of Investigative Dermatology|June 10, 2017
miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in PsoriasisHelen Hermann, Toomas Runnel, Alar Aab, et al.
Journal of Dermatological Science|May 10, 2022
Influence of FLG loss-of-function mutations in host-microbe interactions during atopic skin inflammationPeter Oláh, Eszter Szlávicz, Marcus Kuchner, et al.
The Journal of Investigative Dermatology|April 24, 2025
Cholesterol pathway gene variants and reduced keratinocyte cholesterol support a final common druggable pathway in hyperproliferative inflammatory skin diseasesMelissa Riachi, Dale Bryant, James Ellis, et al.
The Journal of Investigative Dermatology|January 20, 2015
Psoriasis and cardiometabolic traits: modest association but distinct genetic architecturesManja Koch, Hansjörg Baurecht, Janina S Ried, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 17, 2026
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose AdalimumabAnika M Valk, Jolinde van Strien, Ninotska Derksen, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
Nature Genetics|June 27, 2015
The European Genome-phenome Archive of human data consented for biomedical researchIlkka Lappalainen, Jeff Almeida-King, Vasudev Kumanduri, et al.
JCI Insight|February 22, 2023
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding grooveTeresa Tsakok, Jake Saklatvala, Theo Rispens, et al.
The Journal of Investigative Dermatology|June 10, 2017
miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in PsoriasisHelen Hermann, Toomas Runnel, Alar Aab, et al.
Journal of Dermatological Science|May 10, 2022
Influence of FLG loss-of-function mutations in host-microbe interactions during atopic skin inflammationPeter Oláh, Eszter Szlávicz, Marcus Kuchner, et al.
The Journal of Investigative Dermatology|April 24, 2025
Cholesterol pathway gene variants and reduced keratinocyte cholesterol support a final common druggable pathway in hyperproliferative inflammatory skin diseasesMelissa Riachi, Dale Bryant, James Ellis, et al.
The Journal of Investigative Dermatology|January 20, 2015
Psoriasis and cardiometabolic traits: modest association but distinct genetic architecturesManja Koch, Hansjörg Baurecht, Janina S Ried, et al.
Pageof 7